welcome
About us
Newsletter
News Widget
Media Inquiries

Summary

FDA approves ketamine-like drug for TRD

This is a news story, published by Live Science, that relates primarily to FDA news.

mental health treatments news

For more mental health treatments news, you can click here:

more mental health treatments news

Live Science news

For more news from Live Science, you can click here:

more news from Live Science

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like mental health treatments news, you might also like this article about

esketamine treatment

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest regular ketamine news, traditional antidepressant news, mental health treatments news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

antidepressant medication
Live Science

Live Science

•

Health

Health

FDA approves 'ketamine' nasal spray for depression — here's everything you need to know

Live Science
Summary
Nutrition label

75% Informative

Esketamine has been approved as a stand-alone therapy for adults with treatment-resistant depression ( TRD ) The drug is approved only for use in a clinical setting under the supervision of a health care provider.

The FDA approved esketamine under the brand name Spravato in 2019 , but until now, it had to be taken alongside a second antidepressant.

The FDA has approved esketamine's use through a restricted program known as the Spravato Risk Evaluation and Mitigation Strategy (REMS) The program allows patients to take the drug only under the supervision of a health care provider in a clinic and not on their own at home.

There are concerns that unsupervised patients could misuse or abuse the drug.

VR Score

76

Informative language

75

Neutral language

51

Article tone

informal

Language

English

Language complexity

59

Offensive language

possibly offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

External references

19

https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/esketamine-for-treatment-resistant-depressionhttps://pmc.ncbi.nlm.nih.gov/articles/PMC6982454/https://www.spravatorems.com/https://medicine.yale.edu/profile/john-krystal/https://pmc.ncbi.nlm.nih.gov/articles/PMC161656/https://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depressionhttps://pmg.joynadmin.org/documents/1005/664cdd38fe92c34ec0455453.pdfhttps://www.jnj.com/media-center/press-releases/spravato-esketamine-approved-in-the-u-s-as-the-first-and-only-monotherapy-for-adults-with-treatment-resistant-depression#:~:text=Titusville%2C%20New%20Jersey%2C%20January%2021,monotherapy%20for%20adults%20living%20withhttps://www.ema.europa.eu/en/documents/rmp-summary/spravato-epar-risk-management-plan-summary_en.pdfhttps://www.nhs.uk/mental-health/talking-therapies-medicine-treatments/medicines-and-psychiatry/antidepressants/side-effects/https://pmc.ncbi.nlm.nih.gov/articles/PMC10503923/https://www.brighamandwomensfaulkner.org/programs-and-services/psychiatry/ketamine-esketaminehttps://www.spravato.com/https://adf.org.au/drug-facts/dissociatives/https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/SPRAVATO-pi.pdfhttps://pmc.ncbi.nlm.nih.gov/articles/PMC5549850/https://pmc.ncbi.nlm.nih.gov/articles/PMC7690636/https://journals.lww.com/intclinpsychopharm/abstract/2024/03000/differential_effectiveness_between_ketamine_and.9.aspxhttps://www.hopkinsmedicine.org/health/conditions-and-diseases/mood-disorders/treatment-resistant-depression#:~:text=Treatment-resistant%20depression%20affects%20about,diagnosed%20with%20major%20depressive%20disorder.

Source diversity

13

www.hopkinsmedicine.orgpmc.ncbi.nlm.nih.govwww.spravatorems.commedicine.yale.eduwww.jnj.compmg.joynadmin.orgwww.ema.europa.euwww.nhs.ukwww.brighamandwomensfaulkner.orgwww.spravato.comadf.org.auwww.janssenlabels.comjournals.lww.com

Affiliate links

1

https://www.awin1.com/awclick.php?awinmid=2961&awinaffid=103504&clickref=livescience-us-9609246258810315749&p=https%3A%2F%2Fwww.magazinesdirect.com%2Faz-magazines%2F6936539%2Fhow-it-works-magazine-subscription.thtml
Read full article

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.

Powered by Otherweb